Select Your Region
Global
A study to compare different doses of MSTT1041A with a “placebo” – in patients with severe asthma
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
- Respiratory Disorder
- Asthma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Completed
This study runs in
Cities
- abe
- Auckland
- Bakersfield
- Barnaul
- Bellevue
- Berea
- Białystok
- Birmingham
- Boerne
- Brampton
- Brașov
- Bruxelles
- Buenos Aires
- Canton
- Cape Town
- Centennial
- Cercado de Lima
- Charlotte
- Chernivtsi
- Cluj-Napoca
- Colorado Springs
- Craiova
- Dallas
- Dartmouth
- Dnipro
- Fall River
- Florida
- Geesthacht
- gesves
- Houston
- Ivano-Frankivs'k
- Jindřichův Hradec
- Kemerovo
- Kharkiv
- Knoxville
- Kraków
- Kyiv
- Leipzig
- Lima
- Long Beach
- Los Angeles
- Mainz
- McKinney
- Mendoza
- Mississauga
- Moscow
- Moskva
- Murray
- Mykolaiv
- Münster
- Nashville
- New Haven
- New York
- Nottingham
- Novosibirsk
- Odesa
- Oklahoma City
- Ostrava-Poruba
- Ostrów Wielkopolski
- Panama City
- Philadelphia
- Piura
- Providence
- Quilmes
- Québec
- Radom
- Rancho Mirage
- Redwood City
- Richmond
- Rosario
- Ruse
- Ryazan'
- Saint Petersburg
- San Antonio
- San Borja
- San Isidro
- San Miguel de Tucumán
- Sankt-Peterburg
- Seattle
- Seoul
- Sofia
- Spartanburg
- St. Louis
- Stara Zagora
- Stockbridge
- Stockton
- Strakonice
- Tarnów
- Teplice
- Timișoara
- Tomsk
- Toronto
- Towson
- Tucson
- Tulsa
- Twin Falls
- Tábor
- Umkomaas
- Veliko Tarnovo
- Vinnytsia
- Walnut Creek
- Wellington
- Wheat Ridge
- Windsor
- Winter Park
- Wrocław
- Yaroslavl
- Zaporizhzhia
- Łódź
- София
Trial Identifier:
NCT02918019 2016-001549-13 GB39242
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
Study Summary
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT02918019, GB39242, 2016-001549-13
Study Identifier
All
Gender
≥18 Years & ≤ 75 Years
Age
No
Healthy Volunteers
This clinical trial was done to study a new medicine called, “MSTT1041A”, for the treatment of patients with severe asthma. This study was done to find the dose of MSTT1041A that was effective for reducing the number of asthma exacerbations. Other questions that researchers had included finding the dose of MSTT1041A that was effective for improving other symptoms for asthma patients; time it took for MSTT1041A to be distributed in the body; whether MSTT1041A was safe for asthma patients; and whether MSTT1041A caused the immune system to make antibodies against this medicine. There were 502 patients with asthma who took part in this study at 182 study centers in 15 countries.
For the latest version of this information please go to www.forpatients.roche.com